| # | Drug | Count |
|---|---|---|
| 0 | DOXORUBICIN | 37 |
| 1 | CYCLOPHOSPHAMIDE | 33 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 33 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 33 |
| 4 | TESTOSTERONE | 29 |
| 5 | FLUOROURACIL | 23 |
| 6 | FLUOROURACIL CREAM, 0.5% | 23 |
| 7 | TRASTUZUMAB | 23 |
| 8 | PACLITAXEL | 22 |
| 9 | OXALIPLATIN | 19 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LIFILEUCEL | 1 | 0.0035 |
| 1 | TESTOSTERONE | 29 | 0.0012 |
| 2 | TESTOSTERONE ENANTHATE | 2 | 0.0012 |
| 3 | TAFASITAMAB-CXIX | 1 | 0.0011 |
| 4 | AMISULPRIDE | 5 | 0.0008 |
| 5 | RILPIVIRINE | 5 | 0.0007 |
| 6 | ANIDULAFUNGIN | 1 | 0.0006 |
| 7 | DAUNORUBICIN HYDROCHLORIDE | 1 | 0.0006 |
| 8 | TESTOSTERONE UNDECANOATE | 1 | 0.0005 |
| 9 | ONASEMNOGENE ABEPARVOVEC-XIOI | 1 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 36 |
| 1 | Microtubule Inhibitor [EPC] | 36 |
| 2 | Platinum-based Drug [EPC] | 34 |
| 3 | Androgen [EPC] | 29 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 28 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 24 |
| 6 | Aromatase Inhibitor [EPC] | 17 |
| 7 | Corticosteroid [EPC] | 15 |
| 8 | Kinase Inhibitor [EPC] | 13 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 9 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Androgen [EPC] | 29 | 0.0011 |
| 1 | Dopamine-2 Receptor Antagonist [EPC] | 5 | 0.0006 |
| 2 | Endoglycosidase [EPC] | 1 | 0.0005 |
| 3 | Recombinant Human Growth Hormone [EPC] | 9 | 0.0004 |
| 4 | HER2/neu Receptor Antagonist [EPC] | 24 | 0.0003 |
| 5 | Alkaloid [EPC] | 8 | 0.0003 |
| 6 | CD30-directed Immunoconjugate [EPC] | 3 | 0.0003 |
| 7 | CD33-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 8 | Carnitine Analog [EPC] | 1 | 0.0003 |
| 9 | Microtubule Inhibitor [EPC] | 36 | 0.0002 |